Literature DB >> 3233763

Serum procollagen III N-terminal peptide and laminin P1 fragment concentrations in alcoholic liver disease and primary biliary cirrhosis.

R A van Zanten1, R E van Leeuwen, J H Wilson.   

Abstract

Procollagen type III N-peptide (PIII NP) and laminin P1 fragment (LP1) have both been proposed as markers of liver fibrosis. In this study we evaluated the diagnostic application of both peptides in alcoholic liver disease and primary biliary cirrhosis. Serum concentrations of the peptides were measured by radioimmunoassay. PIII NP and LP1 levels appeared to be significantly raised in patients with alcoholic and primary biliary cirrhosis. Patients with alcohol abuse without cirrhosis had normal or slightly elevated PIII NP levels, but significantly raised LP1 levels. There was a strong correlation between PIII NP and LP1 concentrations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3233763     DOI: 10.1016/0009-8981(88)90135-0

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Serum type IV collagen in various liver diseases in comparison with serum 7S collagen, laminin, and type III procollagen peptide.

Authors:  C Hirayama; H Suzuki; A Takada; K Fujisawa; K Tanikawa; S Igarashi
Journal:  J Gastroenterol       Date:  1996-04       Impact factor: 7.527

2.  Serum concentrations of laminin in cirrhosis of the liver.

Authors:  J Collazos; F Díaz; J Genollá
Journal:  Gut       Date:  1993-07       Impact factor: 23.059

3.  Serum laminin, hydrocarbon exposure, and glomerular damage.

Authors:  P Hotz; N Thielemans; A Bernard; F Gutzwiller; R Lauwerys
Journal:  Br J Ind Med       Date:  1993-12

4.  Study of serum procollagen type III peptide in patients with hepatic cirrhosis from a clinical point of view.

Authors:  F Díaz; J Collazos; J Genollá
Journal:  Clin Investig       Date:  1993-05

5.  Panel of three novel serum markers predicts liver stiffness and fibrosis stages in patients with chronic liver disease.

Authors:  Marcin Krawczyk; Simone Zimmermann; Georg Hess; Robert Holz; Marc Dauer; Jochen Raedle; Frank Lammert; Frank Grünhage
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.